Review of Insulin-Dependent and Insulin-Independent Agents for Treating Patients With Type 2 Diabetes Mellitus and Potential Role for Sodium-Glucose Co-Transporter 2 Inhibitors

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin

(2013) John P.H. Wilding   ANNALS OF INTERNAL MEDICINE

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan

(2013) Yehuda Handelsman et al.   Endocrine Practice

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

(2012) B Zambrowicz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comment on: Winkler et al. Histone Deacetylase 6 (HDAC6) Is an Essential Modifier of Glucocorticoid-Induced Hepatic Gluconeogenesis. Diabetes 2012;61:513-523

(2012) R. S. Mahla   DIABETES

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes

(2012) L. B. Katz et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

(2012) R. R. Henry et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

(2012) Charles F Burant et al.   LANCET

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

(2011) K Yamamoto et al.   BRITISH JOURNAL OF PHARMACOLOGY

Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus

(2011) M Pfister et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Relative Expression of a Dominant Mutated ABCC8 Allele Determines the Clinical Manifestation of Congenital Hyperinsulinism

(2011) R. Shemer et al.   DIABETES

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

(2011) R. A. DeFronzo   DIABETES CARE

Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of

(2011) D. Giugliano et al.   DIABETES CARE

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome

(2011) P. U. Feig et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Achieving a clinically relevant composite outcome of an HbA1c of

(2011) B. Zinman et al.   DIABETES OBESITY & METABOLISM

Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies

(2011) Anthony Stonehouse et al.   Diabetes Technology & Therapeutics

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

(2011) A. S. Kalgutkar et al.   DRUG METABOLISM AND DISPOSITION

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

(2011) James F. List et al.   KIDNEY INTERNATIONAL

Effect of kidney disease on glucose handling (including genetic defects)

(2011) Joaquim Calado et al.   KIDNEY INTERNATIONAL

Glucose handling by the kidney

(2011) Amanda Mather et al.   KIDNEY INTERNATIONAL

Pioglitazone and bladder cancer

(2011) Dominique Hillaire-Buys et al.   LANCET

The Effect of Oral Antidiabetic Agents on A1C Levels: A systematic review and meta-analysis

(2010) D. Sherifali et al.   DIABETES CARE

The 11- -Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

(2010) J. Rosenstock et al.   DIABETES CARE

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

(2010) J. M. Gaziano et al.   DIABETES CARE

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

(2010) L. Zhang et al.   DIABETES OBESITY & METABOLISM

Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study

(2010) Riccardo C. Bonadonna et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

Trends in Medication Use Among US Adults With Diabetes Mellitus: Glycemic Control at the Expense of Controlling Cardiovascular Risk Factors

(2009) Devin M. Mann   ARCHIVES OF INTERNAL MEDICINE

Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus

(2009) J. S. FREEMAN   CLEVELAND CLINIC JOURNAL OF MEDICINE

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes

(2009) M. Riddle et al.   DIABETES CARE

Defining and Characterizing the Progression of Type 2 Diabetes

(2009) V. A. Fonseca   DIABETES CARE

Lipid receptors and islet function: therapeutic implications?

(2009) M. A. Kebede et al.   DIABETES OBESITY & METABOLISM

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis

(2009) Panagiotis Anagnostis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

N-Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119

(2009) Zhi-Liang Chu et al.   MOLECULAR ENDOCRINOLOGY

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes

(2009) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy

(2008) Ronald B. Goldberg   ARCHIVES OF INTERNAL MEDICINE

Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin

(2008) Harold E. Bays et al.   ARCHIVES OF INTERNAL MEDICINE

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

(2008) V. A. Fonseca et al.   DIABETES CARE

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

(2008) Zhi-Liang Chu et al.   ENDOCRINOLOGY

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity

(2007) H A Overton et al.   BRITISH JOURNAL OF PHARMACOLOGY